Literature DB >> 29606923

Novel Bile Acid Therapies for Liver Disease.

Saul J Karpen1.   

Abstract

Entities:  

Year:  2018        PMID: 29606923      PMCID: PMC5866303     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


× No keyword cloud information.
  11 in total

1.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Authors:  Brent A Neuschwander-Tetri; Rohit Loomba; Arun J Sanyal; Joel E Lavine; Mark L Van Natta; Manal F Abdelmalek; Naga Chalasani; Srinivasan Dasarathy; Anna Mae Diehl; Bilal Hameed; Kris V Kowdley; Arthur McCullough; Norah Terrault; Jeanne M Clark; James Tonascia; Elizabeth M Brunt; David E Kleiner; Edward Doo
Journal:  Lancet       Date:  2014-11-07       Impact factor: 79.321

2.  norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.

Authors:  Peter Fickert; Gideon M Hirschfield; Gerald Denk; Hanns-Ulrich Marschall; Istvan Altorjay; Martti Färkkilä; Christoph Schramm; Ulrich Spengler; Roger Chapman; Annika Bergquist; Erik Schrumpf; Frederik Nevens; Palak Trivedi; Florian P Reiter; Istvan Tornai; Emina Halilbasic; Roland Greinwald; Markus Pröls; Michael P Manns; Michael Trauner
Journal:  J Hepatol       Date:  2017-05-18       Impact factor: 25.083

Review 3.  New therapeutic concepts in bile acid transport and signaling for management of cholestasis.

Authors:  Michael Trauner; Claudia Daniela Fuchs; Emina Halilbasic; Gustav Paumgartner
Journal:  Hepatology       Date:  2017-03-07       Impact factor: 17.425

Review 4.  Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process.

Authors:  Cyriel Y Ponsioen; Roger W Chapman; Olivier Chazouillères; Gideon M Hirschfield; Tom H Karlsen; Ansgar W Lohse; Massimo Pinzani; Erik Schrumpf; Michael Trauner; Gregory J Gores
Journal:  Hepatology       Date:  2015-12-23       Impact factor: 17.425

5.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Authors:  Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro
Journal:  Gastroenterology       Date:  2013-05-30       Impact factor: 22.682

6.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

Authors:  Frederik Nevens; Pietro Andreone; Giuseppe Mazzella; Simone I Strasser; Christopher Bowlus; Pietro Invernizzi; Joost P H Drenth; Paul J Pockros; Jaroslaw Regula; Ulrich Beuers; Michael Trauner; David E Jones; Annarosa Floreani; Simon Hohenester; Velimir Luketic; Mitchell Shiffman; Karel J van Erpecum; Victor Vargas; Catherine Vincent; Gideon M Hirschfield; Hemant Shah; Bettina Hansen; Keith D Lindor; Hanns-Ulrich Marschall; Kris V Kowdley; Roya Hooshmand-Rad; Tonya Marmon; Shawn Sheeron; Richard Pencek; Leigh MacConell; Mark Pruzanski; David Shapiro
Journal:  N Engl J Med       Date:  2016-08-18       Impact factor: 91.245

Review 7.  Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.

Authors:  Juan P Arab; Saul J Karpen; Paul A Dawson; Marco Arrese; Michael Trauner
Journal:  Hepatology       Date:  2016-08-04       Impact factor: 17.425

Review 8.  Novel bile acid therapeutics for the treatment of chronic liver diseases.

Authors:  Vinod S Hegade; R Alexander Speight; Rachel E Etherington; David E J Jones
Journal:  Therap Adv Gastroenterol       Date:  2016-02-17       Impact factor: 4.409

9.  A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.

Authors:  Kris V Kowdley; Velimir Luketic; Roger Chapman; Gideon M Hirschfield; Raoul Poupon; Christoph Schramm; Catherine Vincent; Christian Rust; Albert Parés; Andrew Mason; Hanns-Ulrich Marschall; David Shapiro; Luciano Adorini; Cathi Sciacca; Tessa Beecher-Jones; Olaf Böhm; Richard Pencek; David Jones
Journal:  Hepatology       Date:  2018-01-29       Impact factor: 17.425

Review 10.  Bile acid receptors as targets for drug development.

Authors:  Frank G Schaap; Michael Trauner; Peter L M Jansen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-08-27       Impact factor: 46.802

View more
  1 in total

1.  Modeling Outcomes in Children With Biliary Atresia With Native Liver After 2 Years of Age.

Authors:  Veena Venkat; Vicky L Ng; John C Magee; Wen Ye; Kieran Hawthorne; Sanjiv Harpavat; Jean P Molleston; Karen F Murray; Kasper S Wang; Nisreen Soufi; Lee M Bass; Estella M Alonso; Jorge A Bezerra; M Kyle Jensen; Binita M Kamath; Kathleen M Loomes; Cara L Mack; Philip Rosenthal; Benjamin L Shneider; Robert H Squires; Ronald J Sokol; Saul J Karpen
Journal:  Hepatol Commun       Date:  2020-10-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.